These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29262900)

  • 1. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
    Deng P; Zhou YL; Wei YL; Li P; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
    Gu WW; Wang JS; Mu K; Ren G
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of Chromosome Abnormality on Therapeutic Efficacy and Prognosis of Newly Diagnosed Multiple Myeloma Treated with Bortezomib].
    Sun C; Wang J; Guo HF; Zhou X; Shen YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):142-146. PubMed ID: 28245391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
    Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
    [No Abstract]   [Full Text] [Related]  

  • 10. [The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment].
    Li F; Xu Y; An G; Hu LP; Zhang YR; Li ZJ; Yuan WP; Cheng T; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):862-7. PubMed ID: 24171960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
    Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
    Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of 1q21 amplification in multiple myeloma].
    Abramova TV; Obukhova TN; Mendeleeva LP; Pokrovskaya OS; Gribanova EO; Ryzhko VV; Grebenyuk LA; Nareyko MV; Solovyev MV; Votyakova OM; Kulikov SM; Rusinov MA; Savchenko VG
    Ter Arkh; 2017; 89(7):32-38. PubMed ID: 28766538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
    An G; Xu Y; Shi L; Shizhen Z; Deng S; Xie Z; Sui W; Zhan F; Qiu L
    Haematologica; 2014 Feb; 99(2):353-9. PubMed ID: 24213147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp.
    Zhou Q; Wen J; Xu F; Yue J; Zhang Y; Su J; Liu Y
    Technol Cancer Res Treat; 2024; 23():15330338241252605. PubMed ID: 38759699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
    Liu Z; Zeng Q; Xiang B
    Medicine (Baltimore); 2021 May; 100(18):e25834. PubMed ID: 33950994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
    Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
    Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of 1q21 Gain in Multiple Myeloma.
    Chen D; Zhou D; Xu J; Zhou R; Ouyang J; Chen B
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e159-e164. PubMed ID: 30685183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.